Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Urovant Sciences Ltd

(NASDAQ: UROV)
Add to Portfolio
-0.05 (-0.35%)
as of Jan 22, 2020

Profile
Ticker Symbol UROV
Exchange NASDAQ
Contact Information
11-12 ST. JAMES S SQUARE SUITE 1 3RD FLOOR
LONDON, X0 GBR
P: 44-20-7400-3347
CEO/President Keith A. Katkin
Earnings at a Glance
Earnings 09/30/19
-0.85
06/30/19
-0.94
03/31/19
-0.77
12/31/18
-0.87
Price Earnings Ratio N/A
EPS Growth 8.52
Most Recent Earnings ($) -0.85
Annual EPS ($) -3.62
Business Summary
Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company's product candidate pipeline consists of vibegron an oral once-daily small molecule beta-3 agonist being evaluated in an international pivotal Phase 3 clinical trial for the treatment of overactive bladder. hMaxi-K is a novel gene therapy being developed for patients with overactive bladder who have failed oral pharmacological therapy. Urovant Sciences Ltd. is based in Floor London United Kingdom.
Industry/Sector SIC-2834 Pharmaceutical Preparations
Medical - Biomedical